HR+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, Systematic Review, Network meta-analysis, Biomarker-driven therapy, Antibody-drug conjugates
Artificial intelligence, LLMs, genomic testing, Oncotype DX ®, decision making, early stage breast cancer